Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.